Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Evaluation of the Onset and Duration of Action of Bepotastine Besilate Ophthalmic Solution in Acute Allergic Conjunctivitis

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Bausch & Lomb Incorporated
ClinicalTrials.gov Identifier:
NCT00424398
First received: January 17, 2007
Last updated: February 13, 2013
Last verified: February 2013
Results First Received: October 8, 2009  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Investigator);   Primary Purpose: Treatment
Condition: Conjunctivitis, Allergic
Interventions: Drug: Bepreve
Drug: Placebo
Drug: Bepotastine Besilate

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Bepreve (Bepotastine Besilate Ophthalmic Solution) 1.5% 1 drop, both eyes at 3 different time points post-CAC within 3 different time points post-dose, for a total of 9 separate time points
Placebo 1 drop, both eyes at 3 different time points post-CAC within 3 different time points post-dose, for a total of 9 separate time points
Bepotastine Besilate Ophthalmic Solution 1.0% 1 drop, both eyes at 3 different time points post-CAC within 3 different time points post-dose, for a total of 9 separate time points

Participant Flow:   Overall Study
    Bepreve (Bepotastine Besilate Ophthalmic Solution) 1.5%     Placebo     Bepotastine Besilate Ophthalmic Solution 1.0%  
STARTED     35     36     36  
COMPLETED     32     35     36  
NOT COMPLETED     3     1     0  
Withdrawal by Subject                 2                 1                 0  
Subject met exclusion criteria                 1                 0                 0  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Bepreve (Bepotastine Besilate Ophthalmic Solution) 1.5% 1 drop, both eyes at 3 different time points post-CAC within 3 different time points post-dose, for a total of 9 separate time points
Placebo 1 drop, both eyes at 3 different time points post-CAC within 3 different time points post-dose, for a total of 9 separate time points
Bepotastine Besilate Ophthalmic Solution 1.0% 1 drop, both eyes at 3 different time points post-CAC within 3 different time points post-dose, for a total of 9 separate time points
Total Total of all reporting groups

Baseline Measures
    Bepreve (Bepotastine Besilate Ophthalmic Solution) 1.5%     Placebo     Bepotastine Besilate Ophthalmic Solution 1.0%     Total  
Number of Participants  
[units: participants]
  35     36     36     107  
Age, Customized  
[units: participants]
       
<18 years     2     2     3     7  
>=18 years     33     34     33     100  
Age  
[units: years]
Mean ± Standard Deviation
  44.3  ± 16.0     40.9  ± 11.4     39.9  ± 15.2     41.7  ± 14.3  
Gender  
[units: participants]
       
Female     18     17     14     49  
Male     17     19     22     58  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Ocular Itching   [ Time Frame: 15 minutes, 8 hours & 16 hours post-dose from Conjunctival Allergen Challenge (CAC) Model ]

2.  Primary:   Conjunctival Redness   [ Time Frame: 15 minutes, 8 hours & 16 hours post-dose from Conjunctival Allergen Challenge (CAC) Model ]

3.  Secondary:   Ciliary Redness   [ Time Frame: 15 Minutes, 8 Hours & 16 Hours post-dose from Conjunctival Allergen Challenge (CAC) Model ]

4.  Secondary:   Episcleral Redness   [ Time Frame: 15 Minutes, 8 Hours & 16 Hours post-dose from Conjunctival Allergen Challenge (CAC) Model ]

5.  Secondary:   Chemosis   [ Time Frame: 15 Minutes, 8 Hours & s6 Hours post-dose from Conjunctival Allergen Challenge (CAC) Model ]

6.  Secondary:   Rhinorrhea (Runny Nose)   [ Time Frame: 15 Minutes, 8 Hours & 16 Hours post-dose from Conjunctival Allergen Challenge (CAC) Model ]

7.  Secondary:   Nasal Pruritus (Itchy Nose)   [ Time Frame: 15 Minutes, 8 Hours & 16 Hours post-dose from Conjunctival Allergen Challenge (CAC) Model ]

8.  Secondary:   Ear or Palate Pruritus (Itchy Ear or Palate)   [ Time Frame: 15 Minutes, 8 Hours & 16 Hours post-dose from Conjunctival Allergen Challenge (CAC) Model ]

9.  Secondary:   Nasal Congestion   [ Time Frame: 15 Minutes, 8 Hours & 16 Hours post-dose from Conjunctival Allergen challenge (CAC) Model ]

10.  Secondary:   Tearing   [ Time Frame: 15 Minutes, 8 Hours & 16 Hours post-dose from Conjunctival Allergen Challenge (CAC) Model ]

11.  Secondary:   Ocular Mucus Discharge   [ Time Frame: 15 Minutes, 8 Hours & 16 Hours post-dose from Conjunctival Allergen Challenge (CAC) Model ]

12.  Secondary:   Eyelid Swelling   [ Time Frame: 15 Minutes, 8 Hours & 16 Hours post-dose from Conjunctival Allergen Challenge (CAC) Model ]

13.  Secondary:   Total Nasal Symptom   [ Time Frame: 15 Minutes, 8 Hours & 16 Hours post-dose from Conjunctival Allergen Challenge (CAC) Model ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Vice President, Clinical Research & Medical Affairs
Organization: ISTA Pharmaceuticals, Inc.
phone: 949-788-6000
e-mail: tmcnamara@istavision.com


No publications provided by Bausch & Lomb Incorporated

Publications automatically indexed to this study:

Responsible Party: Bausch & Lomb Incorporated
ClinicalTrials.gov Identifier: NCT00424398     History of Changes
Other Study ID Numbers: ISTA-BEPO-CS01
Study First Received: January 17, 2007
Results First Received: October 8, 2009
Last Updated: February 13, 2013
Health Authority: United States: Food and Drug Administration